Immutep Ltd Borrow Rate Increases to 117.72%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 08 2026
0mins
Latest data shows the largest indicative borrow rate increases among liquid option names include: Immutep Ltd (IMMP) 117.72% +5.51, Merlin Inc (MRLN) 86.35% +3.04, T-REX 2X Long BMNR Daily Target ETF (BMNU) 18.58% +0.98, PROSHARES ULTRA BITCOIN ETF (BITU) 8.22% +0.65, CrowdGather Inc (CRWG) 8.91% +0.51, iShares Germany (EWG) 8.37% +0.50, LAR Stock (LAR) 1.98% +0.50, Canadian Natural (CNQ) 0.76% +0.46, ProShares UltraShort QQQ (QID) 2.60% +0.45, and Red Cat Holdings (RCAT) 2.05% +0.43.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMMP
Wall Street analysts forecast IMMP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.389
Low
12.00
Averages
12.00
High
12.00
Current: 0.389
Low
12.00
Averages
12.00
High
12.00
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immutep ADRs Class Action Notice Issued
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, that they must apply to be lead plaintiff by July 6, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Immutep concealed critical clinical data regarding the TACTI-004 trial, resulting in investor losses when the true information became public, highlighting significant deficiencies in the company's transparency in clinical trials.
- Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
- Investor Selection Advice: Investors are advised to choose law firms with proven success to ensure effective legal support in class actions, avoiding those that merely act as intermediaries without substantial litigation experience.
See More
Immutep Limited Faces Investor Misleading Allegations
- Lawsuit Background: On May 5, 2026, a class action was filed against Immutep Limited (IMMP), alleging that the company misled investors regarding the progress of its drug candidate TACTI-004 between March 24, 2025, and March 12, 2026.
- Clinical Trial Issues: The complaint states that Immutep falsely claimed “strong operational progress” in the TACTI-004 trial while concealing internal data indicating a significant risk of failing to meet primary efficacy and safety endpoints.
- Stock Price Plunge: Following the announcement on March 13, 2026, that the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 trial, Immutep's ADR price plummeted from $2.76 to $0.48, an 83% decline, severely impacting investor confidence.
- Shareholder Action Advice: Affected shareholders are encouraged to submit their papers by July 6, 2026, to serve as lead plaintiffs in the class action, highlighting the importance of corporate governance and shareholder rights.
See More
Immutep ADRs Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, to apply as lead plaintiffs by July 6, 2026, to participate in the class action without incurring any fees.
- Lawsuit Background: The lawsuit alleges that Immutep concealed negative information regarding the TACTI-004 trial, leading to investor losses when the truth was revealed, highlighting potential mismanagement of clinical trial data by the company.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, demonstrating its successful track record and expertise in this field.
- Investor Selection Advice: Investors are advised to carefully choose legal counsel to avoid partnering with inexperienced intermediaries, ensuring effective legal representation and support in the class action.
See More
Immutep Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Immutep Limited for violations of securities laws, involving securities purchases from March 24, 2025, to March 12, 2026, with a deadline to contact the firm by July 6, 2026, for participation.
- False Statement Allegations: The complaint alleges that Immutep concealed critical results from its TACTI-004 trial, as the company claimed “strong operational progress” in a SEC Form-K filed on January 30, 2026, despite knowing the trial would not meet its primary efficacy endpoints, leading to investor losses.
- Legal Representation Information: The Schall Law Firm offers free consultations and encourages affected investors to contact Brian Schall to understand their rights and participate in the lawsuit, highlighting the firm's specialization in securities class actions and shareholder rights litigation.
- Lawsuit Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who take no action will be considered absent class members, underscoring the importance of participating in the lawsuit.
See More
IMMP Stock Plummets 83% Following Trial Discontinuation
- Stock Collapse: Immutep's shares plummeted 83% on March 13, 2026, after the company disclosed the discontinuation of its TACTI-004 Phase III trial for futility, with the stock price dropping from $2.76 to $0.48, resulting in significant losses for investors.
- False Trial Progress Claims: Between March 24, 2025, and March 12, 2026, Immutep repeatedly claimed that the TACTI-004 trial was progressing well, while internal data indicated a high risk of failure, leading to a decline in investor trust and confidence in the company.
- Legal Action Initiated: Affected investors are encouraged to contact SueWallSt for potential compensation, with a deadline of July 6, 2026, highlighting serious concerns about the company's disclosure practices and their impact on market fairness.
- Investor Rights Protection: Investors who sold their IMMP shares during the class period can still participate in the lawsuit, emphasizing the legal system's commitment to protecting investor rights and ensuring accountability for corporate misrepresentation.
See More
Immutep Faces Class Action Lawsuit Impacting Stock Price Dramatically
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Immutep, alleging securities fraud and other unlawful business practices, with investors advised to apply as Lead Plaintiff by July 6, 2026, indicating significant legal risks that could tarnish the company's reputation.
- Trial Discontinuation: On March 13, 2026, Immutep disclosed that the Independent Data Monitoring Committee recommended halting the TACTI-004 Phase III trial, which evaluates eftilagimod alfa in non-small cell lung cancer patients, potentially hindering the company's R&D progress in a competitive market.
- Stock Price Plunge: Following this news, Immutep's American Depositary Receipt (ADR) price plummeted by $2.27, or 82.44%, closing at $0.48 on March 13, 2026, reflecting extreme pessimism in the market regarding the company's future prospects.
- Legal Firm Background: Pomerantz LLP, a leading firm in securities class litigation with over 85 years of experience, focuses on advocating for victims of securities fraud, and this lawsuit may attract further investor scrutiny, exacerbating the legal and financial pressures faced by Immutep.
See More
Immutep ADRs Class Action Notice Issued
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, that they must apply to be lead plaintiff by July 6, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Immutep concealed critical clinical data regarding the TACTI-004 trial, resulting in investor losses when the true information became public, highlighting significant deficiencies in the company's transparency in clinical trials.
- Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
- Investor Selection Advice: Investors are advised to choose law firms with proven success to ensure effective legal support in class actions, avoiding those that merely act as intermediaries without substantial litigation experience.
See More
Immutep Limited Faces Investor Misleading Allegations
- Lawsuit Background: On May 5, 2026, a class action was filed against Immutep Limited (IMMP), alleging that the company misled investors regarding the progress of its drug candidate TACTI-004 between March 24, 2025, and March 12, 2026.
- Clinical Trial Issues: The complaint states that Immutep falsely claimed “strong operational progress” in the TACTI-004 trial while concealing internal data indicating a significant risk of failing to meet primary efficacy and safety endpoints.
- Stock Price Plunge: Following the announcement on March 13, 2026, that the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 trial, Immutep's ADR price plummeted from $2.76 to $0.48, an 83% decline, severely impacting investor confidence.
- Shareholder Action Advice: Affected shareholders are encouraged to submit their papers by July 6, 2026, to serve as lead plaintiffs in the class action, highlighting the importance of corporate governance and shareholder rights.
See More
Immutep ADRs Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, to apply as lead plaintiffs by July 6, 2026, to participate in the class action without incurring any fees.
- Lawsuit Background: The lawsuit alleges that Immutep concealed negative information regarding the TACTI-004 trial, leading to investor losses when the truth was revealed, highlighting potential mismanagement of clinical trial data by the company.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, demonstrating its successful track record and expertise in this field.
- Investor Selection Advice: Investors are advised to carefully choose legal counsel to avoid partnering with inexperienced intermediaries, ensuring effective legal representation and support in the class action.
See More
Immutep Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Immutep Limited for violations of securities laws, involving securities purchases from March 24, 2025, to March 12, 2026, with a deadline to contact the firm by July 6, 2026, for participation.
- False Statement Allegations: The complaint alleges that Immutep concealed critical results from its TACTI-004 trial, as the company claimed “strong operational progress” in a SEC Form-K filed on January 30, 2026, despite knowing the trial would not meet its primary efficacy endpoints, leading to investor losses.
- Legal Representation Information: The Schall Law Firm offers free consultations and encourages affected investors to contact Brian Schall to understand their rights and participate in the lawsuit, highlighting the firm's specialization in securities class actions and shareholder rights litigation.
- Lawsuit Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who take no action will be considered absent class members, underscoring the importance of participating in the lawsuit.
See More
IMMP Stock Plummets 83% Following Trial Discontinuation
- Stock Collapse: Immutep's shares plummeted 83% on March 13, 2026, after the company disclosed the discontinuation of its TACTI-004 Phase III trial for futility, with the stock price dropping from $2.76 to $0.48, resulting in significant losses for investors.
- False Trial Progress Claims: Between March 24, 2025, and March 12, 2026, Immutep repeatedly claimed that the TACTI-004 trial was progressing well, while internal data indicated a high risk of failure, leading to a decline in investor trust and confidence in the company.
- Legal Action Initiated: Affected investors are encouraged to contact SueWallSt for potential compensation, with a deadline of July 6, 2026, highlighting serious concerns about the company's disclosure practices and their impact on market fairness.
- Investor Rights Protection: Investors who sold their IMMP shares during the class period can still participate in the lawsuit, emphasizing the legal system's commitment to protecting investor rights and ensuring accountability for corporate misrepresentation.
See More
Immutep Faces Class Action Lawsuit Impacting Stock Price Dramatically
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Immutep, alleging securities fraud and other unlawful business practices, with investors advised to apply as Lead Plaintiff by July 6, 2026, indicating significant legal risks that could tarnish the company's reputation.
- Trial Discontinuation: On March 13, 2026, Immutep disclosed that the Independent Data Monitoring Committee recommended halting the TACTI-004 Phase III trial, which evaluates eftilagimod alfa in non-small cell lung cancer patients, potentially hindering the company's R&D progress in a competitive market.
- Stock Price Plunge: Following this news, Immutep's American Depositary Receipt (ADR) price plummeted by $2.27, or 82.44%, closing at $0.48 on March 13, 2026, reflecting extreme pessimism in the market regarding the company's future prospects.
- Legal Firm Background: Pomerantz LLP, a leading firm in securities class litigation with over 85 years of experience, focuses on advocating for victims of securities fraud, and this lawsuit may attract further investor scrutiny, exacerbating the legal and financial pressures faced by Immutep.
See More
